



Eosinophil: Current Status and Future Perspectives

Guest Editor:

Prof. Dr. Ildiko Horvath

1. National Koranyi Institute for
Pulmonology, Budapest,
Hungary
2. Department of Pulmonology,
University of Debrecen,
Debrecen, Hungary

Deadline for manuscript
submissions:

31 August 2024

Message from the Guest Editor

Dear Colleagues,

This Special Issue invites research articles and reviews that investigate the complex biology of eosinophils, including their activation, migration, and effector functions. It seeks to understand how eosinophils contribute to the resolution of infections, their role in maintaining tissue homeostasis, and their involvement in allergic and inflammatory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and eosinophilic disorders together with cancers.

Furthermore, this Special Issue encourages studies that explore the potential of eosinophils as therapeutic targets, particularly in the context of allergic diseases and cancer, where they have been implicated in both tumor suppression and promotion. It also welcomes research on the development of novel diagnostic tools, predictive biomarkers, and therapeutic strategies to modulate eosinophil activity, with the goal of improving clinical outcomes for patients.

Prof. Dr. Ildiko Horvath
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)